B
MRVI icon

Bailard’s Maravai LifeSciences MRVI Stock Holding History

Bailard’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-62,375
Closed -$1.59M – 758
2022
Q3 		$1.59M Sell
62,375
-5,820
-9% -$146K 0.07% 204
2022
Q2 		$1.94M Buy
68,195
+2,060
+3% +$65.3K 0.08% 191
2022
Q1 		$2.33M Sell
66,135
-9
-0% -$302 0.08% 195
2021
Q4 		$2.77M Buy
66,144
+1,004
+2% +$40.7K 0.09% 173
2021
Q3 		$3.2M Hold
65,140
– – 0.11% 155
2021
Q2 		$2.72M Sell
65,140
-7,798
-11% -$302K 0.09% 169
2021
Q1 		$2.6M Buy
+72,938
New +$2.42M 0.1% 173

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
OCBV
Ownership Capital B.V. Amsterdam, Netherlands $178M AUM 4.75% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Bailard's MRVI Position: Q4 2022 in Review

Bailard sold out of Maravai LifeSciences (MRVI) in Q4 2022, closing a stake of 62,375 shares — an estimated $1.59M sold.

Bailard first reported a position in MRVI in Q1 2021 and held it in 7 quarters. The position peaked at $3.2M in Q3 2021. 212 funds tracked by Wall St. Rank hold MRVI as of Q4 2022.

  • Bailard reported no remaining Maravai LifeSciences position as of Q4 2022 after selling out during the quarter.
  • Bailard sold 62,375 Maravai LifeSciences shares in Q4 2022, an estimated $1.59M.
  • Bailard first reported a position in Maravai LifeSciences in Q1 2021 and held it in 7 quarters.
  • Bailard's Maravai LifeSciences position peaked at $3.2M in Q3 2021.
  • 212 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q4 2022.

Based on Bailard's 13F filing for Q4 2022, filed 2 Feb 2023.